| Relief Therapeutics–SEVERAL: investment, 202107 private placement CHF15m with 71.4m common stock at CHF0.21/share to two US institutional investors |
2021-07-26 |
| Abivax–SEVERAL: credit, 202107– convertible bonds €25m at 6% interest/year |
2021-07-23 |
| Abivax–SEVERAL: investment, 202107 capital increase €60m with 3% discount with 1.97m shares at €30.55/share |
2021-07-23 |
| Anocca–SEVERAL: investment, 202107 financing round Series B SEK400m ($47m) led by Danske Bank |
2021-07-22 |
| Sophia Genetics–SEVERAL: investment, 202107 US IPO $234m+$35.1m with 13m+1.95m ordinary shares at $18/Share at Nasdaq Global Select Market |
2021-07-22 |
| Coave Therapeutics–Eurazeo: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor Idinvest |
2021-07-21 |
| Coave Therapeutics–eureKARE: investment, 202107 financing round Series B extension totalling €21.2m incl new + co-investor eureKARE |
2021-07-21 |
| Coave Therapeutics–Fund+: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor Fund+ |
2021-07-21 |
| Coave Therapeutics–GO Capital (FR): investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor GO Capital |
2021-07-21 |
| Coave Therapeutics–Huntsworth: public relations, 202107 service existent by Medistrava Consulting |
2021-07-21 |
| Coave Therapeutics–Kurma Partners: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor Kurma Partners |
2021-07-21 |
| Coave Therapeutics–Omnes Capital: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor Omnes Capital |
2021-07-21 |
| Coave Therapeutics–Seroba: investment, 202107 financing round Series B extension totalling €21.2m incl lead investor Seroba Life Sciences |
2021-07-21 |
| Coave Therapeutics–SEVERAL: investment, 202107 financing round Series B extension €21.2m bringing total Series B to €33.1m |
2021-07-21 |
| Coave Therapeutics–Sham: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor Sham Innovation Santé |
2021-07-21 |
| Coave Therapeutics–Théa Open Innovation: investment, 202107 financing round Series B extension totalling €21.2m incl new + co-investor Théa OI |
2021-07-21 |
| Coave Therapeutics–V-Bio Ventures: investment, 202107 financing round Series B extension totalling €21.2m incl existing + co-investor V-Bio Ventures |
2021-07-21 |
| Excellims–Covalent Bonds: public relations, 202107 service existent by Covalent Bonds |
2021-07-21 |
| 3a-Diagnostics–XPhyto Therapeutics: investment, 202107– 202110 acqisition 100% €400k upfront + €3.5m at closing ANNOUNCED |
2021-07-20 |
| Panakès Partners–EU (govt): investment, 202107 first closing totalling €150m of Purple Fund incl co-lead investor EIF |
2021-07-20 |
| Panakès Partners–Italy (govt): investment, 202107 first closing totalling €150m of Purple Fund incl co-lead investor CDP Venture Capital FoF |
2021-07-20 |
| Panakès Partners–SEVERAL: investment, 202107 first closing €150m of Purple Fund |
2021-07-20 |
| Intelligent Tissue Group–BioIVT: investment, 202107 acquisition €na of Tissue Solutions Ltd by BioIVT |
2021-07-19 |
| Dopavision–Akampion: public relations, 202107 service existent by Akampion |
2021-07-14 |
| Dopavision–Boehringer: investment, 202107 financing round Series A totalling €12m incl existing + co-investor BIVF |
2021-07-14 |
| Dopavision–BPCE: investment, 202107 financing round Series A totalling €12m incl new + lead investor Seventure Partners |
2021-07-14 |
| Dopavision–Eternity.Health: investment, 202107 financing round Series A totalling €12m incl existing + co-investor Ababax Health |
2021-07-14 |
| Dopavision–Novartis: investment, 202107 financing round Series A totalling €12m incl new + co-investor Novartis Pharmaceuticals |
2021-07-14 |
| Dopavision–SEVERAL: investment, 202107 financing round Series A €12m led by new investor Seventure Partners |
2021-07-14 |
| Immunic–SEVERAL: investment, 202107 underwritten public offering $45m with 4.5m shares common stock at $10/share |
2021-07-14 |
| Kriya Therapeutics–SEVERAL: investment, 202107 financing round Series B $100m led by Patient Square Capital + incl new + existing investors |
2021-07-14 |
| Mobilion–SEVERAL: investment, 202107 financing round Series C $60m led by new investor D1 Capital Partners |
2021-07-13 |
| Vectura–Philip Morris: investment, 202107– acquisition recommended cash tender offer GBP852m at150p/share |
2021-07-09 |
| Exscientia–Gates Foundation: grant, 202107– grant $1.5m for AI-based design of Mpro inhibitors for COVID-19 from GF + Gates Philanthropy Partners |
2021-07-08 |
| Micropep Technologies–CEA Industrie: investment, 202107 financing round Series A totalling €8.5m incl new + lead investor Supernova Invest |
2021-07-08 |
| Micropep Technologies–FMC: investment, 202107 financing round Series A totalling €8.5m incl new + co-investor FMC Ventures |
2021-07-08 |
| Micropep Technologies–IRDI Soridec: investment, 202107 financing round Series A totalling €8.5m incl existing + co-investor IRDI Capital |
2021-07-08 |
| Micropep Technologies–SEVERAL: investment, 202107 financing round Series A €8.5m led by Supernova Invest |
2021-07-08 |
| Micropep Technologies–Sofinnova: investment, 202107 financing round Series A totalling €8.5m incl existing + co-investor Sofinnova Partners |
2021-07-08 |
| Theolytics–Merck (DE): investment, 202107 financing round Series A expansion incl new investor M Ventures |
2021-07-08 |
| Theolytics–Otsuka: investment, 202107 financing round Series A expansion incl existing investor Taiho Ventures |
2021-07-08 |
| Theolytics–SEVERAL: investment, 202107 financing round Series A expansion incl new investor M Ventures |
2021-07-08 |
| Theolytics–Univ Oxford: investment, 202107 financing round Series A expansion incl existing investor Univ Oxford |
2021-07-08 |
| Nerre Therapeutics–Advent Venture Partners: investment, 202107 financing round Series B2 totalling £20m incl existing + co-investor Advent LS |
2021-07-07 |
| Nerre Therapeutics–Columbus Venture Partners: investment, 202107 financing round Series B2 totalling £20m incl new + lead investor Columbus VP |
2021-07-07 |
| Nerre Therapeutics–Consilium: public relations, 202107 service existent by Consilium Strategic Communications |
2021-07-07 |
| Nerre Therapeutics–Forbion: investment, 202107 financing round Series B2 totalling £20m incl existing + co-investor Forbion Capital Partners |
2021-07-07 |
| Nerre Therapeutics–Fountain Healthcare Partners: investment, 202107 financing round Series B2 totalling £20m incl existing + co-investor Fountain HP |
2021-07-07 |
| Nerre Therapeutics–OrbiMed: investment, 202107 financing round Series B2 totalling £20m incl existing + co-investor OrbiMed |
2021-07-07 |
| Nerre Therapeutics–SEVERAL: investment, 202107 financing round Series B2 £20m led by Columbus Venture Partners |
2021-07-07 |
| Nerre Therapeutics–United Kingdom (govt): investment, 202107 financing round Series B2 totalling £20m incl existing + co-investor UK Future Fund |
2021-07-07 |
| Cutanos–High-Tech Gründerfonds: investment, 202107 1st financing round incl investor HTGF |
2021-07-05 |
| Cutanos–IST Cube: investment, 202107 1st financing round incl investor IST Cube |
2021-07-05 |
| Cutanos–Khanu Management: investment, 202107 1st financing round incl investor KHAN Technology Transfer Fund I |
2021-07-05 |
| Cutanos–OTHER: investment, 202107 1st financing round incl a private investor |
2021-07-05 |
| Cutanos–SEVERAL: investment, 202107 1st financing round with KHAN-I + HTGF + IST Cube + another private investor |
2021-07-05 |
| CellGenix–Sartorius: investment, 202107 acquisition 51% share for €100m cash by SSB with planned acquisition of remaining shares until 2026 |
2021-07-02 |
| Fertin Pharma–Philip Morris: investment, 202107– acquisition DKK5.1b ($820m) from EQT + Bagger-Sørensen ANNOUNCED |
2021-07-01 |
| GeneWerk–Ampersand: investment, 202107 investment existent GeneWerk GmbH is portfolio company of Ampersand |
2021-07-01 |
| Nestlé–Seres Therapeutics: microbiome-based drug, 202107– license North America $175m upfront + $350m milestones + 50% of commercial profits |
2021-07-01 |
| Zukunftsfonds Heilbronn–Ampersand: investment, 202107 acquisition of majority share in PPS from ZFHN and merger with portfolio company GeneWerk |
2021-07-01 |
| Promethera–SEVERAL: investment, 202106– financing round €20m incl €10m from Shang Ying Intl Holdings Ltd (HK) |
2021-06-30 |
| Orbit Discovery–Zyme Communications: public relations, 202106 service existent by Zyme |
2021-06-29 |
| United Kingdom (govt)–Univ Edinburgh: CAGT manufacturing, 202106– collab establishment of CGT Catapult Edinburgh at EdinBurgh BioQuarter |
2021-06-29 |
| BMS–WPP: public releations, 202106c supply service BMS is among largest + long-term health clients of Ogilvy Health |
2021-06-28 |
| Boehringer–WPP: public releations, 202106c supply service Boehringer is among largest + long-term health clients of Ogilvy Health |
2021-06-28 |
| Merck (US)–WPP: public releations, 202106c supply service Merck is among largest + long-term health clients of Ogilvy Health |
2021-06-28 |
| Pfizer–WPP: public releations, 202106c supply service Pfizer is among largest + long-term health clients of Ogilvy Health |
2021-06-28 |
| Polyphor–LifeSci: public relations, 202106 supply service existent LifeSci Advisors is media + IR contact for Polyphor |
2021-06-28 |
| Discover Echo–Cellink: investment, 202106– acquisition $110m with $98m in cash + $12m in new Series B shares ANNOUNCED |
2021-06-26 |
| Pixium Vision–LifeSci: public relations, 202106 supply service existent LifeSci Advisors is media + IR contact for Pixium Vision |
2021-06-25 |
| EQRx–Exscientia: AI-based drug discovery, 202106– strategic collab r+d + commerc with equally shared costs |
2021-06-24 |
| Merck (DE)–Nucleai MD: AI-based biomarker discovery, 202106– long-term collab using ATOM platform for cancer biomarker discovery |
2021-06-24 |
| RheinCell Therapeutics–Catalent: investment, 202106– acquisition of RheinCell by Catalent ANNOUNCED |
2021-06-24 |
| Cambridge Cancer Genomics–Dante Labs: investment, 202106 acquisition of CCG.ai by Dante Labs |
2021-06-23 |
| FundaMental Pharma–High-Tech Gründerfonds: investment, 202106 seed funding from HTGF |
2021-06-23 |
| Leukocare–Petrichor Healthcare: credit, 202106– convertible loan totalling $15m incl Petrichor HCM |
2021-06-23 |
| Leukocare–Petrichor Healthcare: investment, 202106 equity investment $2.5m from Petrichor HCM |
2021-06-23 |
| Leukocare–SEVERAL: credit, 202106– convertible loan $15m led by Petrichor HCM + incl existing shareholders |
2021-06-23 |
| Monte Rosa Therapeutics–SEVERAL: investment, 202106 IPO $222.3m+$33.345m with 11.7m+1.755m shares common stock at Nasdaq Global Select Market |
2021-06-23 |
| Paramit–Tecan: investment, 202106– acquisition $1b from Altaris Capital Partners LLC ANNOUNCED |
2021-06-23 |
| 908 Devices–Sartorius: bioprocess control technology, 202106 collab product integration Rebel media analyzer with SIMCA data exploratory tool |
2021-06-22 |
| 908 Devices–Securecell: bioprocess control technology, 202106 collab product integration Rebel media analyzer with Lucullus PIMS |
2021-06-22 |
| Corlieve Therapeutics–Uniqure: investment, 202106– acquisition €46.3m upfront cash + €203.7m milestones ANNOUNCED |
2021-06-22 |
| Sirion Biotech–PerkinElmer: investment, 202106– acquisition by PerkinElmer ANNOUNCED |
2021-06-22 |
| Owler–Meltwater: investment, 202106– acquisition $24.5m with $18.9m in cash + $5.6m in equity ANNOUNCED |
2021-06-18 |
| Aldevron–Danaher: investment, 202106– acquisition $9.6b in cash by Danaher ANNOUNCED |
2021-06-17 |
| Apollo Therapeutics Fund–SEVERAL: investment, 202106 financing round $145m led by Patient Square Capital taking controlling equity position |
2021-06-17 |
| Chemic Laboratories–Solvias: investment, 202106 acquisition €na by Solvias |
2021-06-17 |
| Kahr-Medical–aMoon: investment, 202106 financing round totalling $46.5m incl lead investor aMoon |
2021-06-16 |
| Kahr-Medical–BVF Partners: investment, 202106 financing round totalling $46.5m incl new + co-investor BVF Partners LP |
2021-06-16 |
| Kahr-Medical–Cancer Focus Fund: investment, 202106 financing round totalling $46.5m incl new + co-investor Cancer Focus Fund |
2021-06-16 |
| Kahr-Medical–Dafna Capital: investment, 202106 financing round totalling $46.5m incl new + co-investor Dafna Capital Management LLC |
2021-06-16 |
| Kahr-Medical–Flerie Invest: investment, 202106 financing round totalling $46.5m incl existing + co-investor Flerie Invest AB |
2021-06-16 |
| Kahr-Medical–Hadasit Bio-Holdings: investment, 202106 financing round totalling $46.5m incl existing + co-investor Hadasit Bio Holdings Ltd |
2021-06-16 |
| Kahr-Medical–Mirae Asset: investment, 202106 financing round totalling $46.5m incl existing + co-investor Mirae Asset |
2021-06-16 |
| Kahr-Medical–Oriella: investment, 202106 financing round totalling $46.5m incl existing + co-investor Oriella Ltd |
2021-06-16 |
| Kahr-Medical–Pavilion Capital: investment, 202106 financing round totalling $46.5m incl existing + co-investor Pavilion Capital |
2021-06-16 |
| Kahr-Medical–Peregrine Ventures: investment, 202106 financing round totalling $46.5m incl new + co-investor Peregrine Ventures |
2021-06-16 |
| Kahr-Medical–SEVERAL: investment, 202106 financing round $46.5m led by aMoon |
2021-06-16 |
![[LSE] Life-Sciences-Europe.com - The European Life Sciences Web Portal](/images/basics/lse-life-sciences-europe-portal-logo-2019.png){kind=logo}
Date
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20111029-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [MSC] Mass-Spec-Capital.com – The Mass Spectrometry Web Portal 120x600px](/banner/iito-20181119-120-600-msc-mass-spec-capital-com.jpg)
